James W. Parker, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 971 South Highway 27, Somerset, KY 42501 Phone: 606-451-0239 Fax: 606-451-9640 |
Sanaa Abdel-rahman Mahmoud, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 110 Hardin Ln, Ste 3, Somerset, KY 42503 Phone: 606-451-0115 Fax: 606-451-0155 |
Dr. Sarah A. Bozeman, D.O. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 971 South Highway 27, Somerset, KY 42003 Phone: 606-451-0239 Fax: 855-656-7325 |
News Archive
Prescription Solutions, a leading pharmacy benefits management (PBM) organization and a UnitedHealth Group (NYSE:UNH) company, today announced that it received the highest rankings for customer service and cost competitiveness factors among mail order pharmacies in the J.D. Power and Associates 2009 National Pharmacy StudySM.
A research team led by Associate Professor Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL) has developed a sensitive and accurate way of identifying gene copy number variations (CNVs).
Researchers at the Norwegian University of Science and Technology are pioneering the use of a radioactive tracer in combination with PET MRI imaging to help some prostate cancer patients avoid lengthy and unnecessary surgery.
Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.
Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%.
› Verified 5 days ago